Bevacizumab, Inhibitor

Bevacizumab

Cat. Num. AAA5759549

• Purity: 99.1%
• Synonyms: Bevacizumab; Bevacizumab(anti-VEGF); anti-VEGF; rhuMab VEGF; inhibitor

• Purity/Purification: 99.1%
• Form/Format: Solid. Powder

• Solubility: <1mg/ml refers to the product slightly soluble or insoluble
• CAS Number: 216974-75-3
• Target & IC50: VEGF
• Cell Research: Human umbilical vein endothelial cells (HUVECs) (1x104 cells/100uL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10uL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450nM to determine the cell viability[2]. Cell lines: HUVECs
• Kinase Assay: The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30 degree C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200uL per well of diluted samples (VEGF) or buffer and agitated at 1000rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10ug/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10ug/mL, 3ug/mL and 1ug/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Related Product Information for Bevacizumab, inhibitor

Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.

Product Categories/Family for Bevacizumab, inhibitor

Angiogenesis; VEGFR

References

Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment,in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment,in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.
Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.
Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.
Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.